-
外観
白色〜わずかにうすい黄色, 結晶性粉末〜粉末
-
溶解性
N,N-ジメチルホルムアミドに可溶
-
用途
チアゾリジン系PPARγ 作用
剤です。インスリン抵抗性を改善し、血糖低
下作用を示します。
-
用途
チアゾリジン系PPARγ作用 剤です。インスリン抵抗性を改善し、血糖低 下作用を示します。
-
効能
糖尿病治療薬, ペルオキシソーム増殖因子活性化受容体(PPAR)γ作動薬
-
商品名
アクトス (武田テバ薬品); アクトス (武田テバ薬品)
-
説明
Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of non-insulin dependent diabetes mellitus
(NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester
into thiazolidine with thiourea. As with other representatives in this
class, it potently activates the nuclear receptor peroxisome proliferator-activated
receptor gamma which is believed to be involved in the regulation of insulin
resistance and adipogenesis. In several obese and obese diabetic animal
models, treatment with Pioglitazone resulted in reductions in plasma glucose
and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs or insulin, was shown
to significantly improve glycemic control in type-2 diabetes and demonstrated a
beneficial effect on insulin resistance and other clinically relevant parameters as
plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be
safe and well tolerated and is said to have a lower occurrence of hepatic toxicity
as well as a low probability for drug interaction.
-
化学的特性
Colourless Prisms
-
使用
Pioglitazone hydrochloride is a euglycemic agent,used as an antidiabetic.
-
一般的な説明
Pioglitazone hydrochloride is an oral antidiabetic agent used in the treatment of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes.
